Cargando…

Recent knowledge in favor of remdesivir (GS-5734) as a therapeutic option for the COVID-19 infections

The management of SARS-CoV-2 has not yet been clearly determined and is based on potential therapies evaluated during the SARS-CoV and MERS-CoV outbreaks. An emerging potential therapeutic approach currently being evaluated in numerous clinical trials is the remdesivir agent, which acts on COVID-19...

Descripción completa

Detalles Bibliográficos
Autores principales:	Saqrane, S., El Mhammedi, M.A., Lahrich, S., Laghrib, F., El Bouabi, Y., Farahi, A., Bakasse, M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences. 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8039503/ https://www.ncbi.nlm.nih.gov/pubmed/33857725 http://dx.doi.org/10.1016/j.jiph.2021.02.006

Ejemplares similares

Current progress on COVID-19 related to biosensing technologies: New opportunity for detection and monitoring of viruses
por: Laghrib, F., et al.
Publicado: (2021)

Review on the contamination of wastewater by COVID-19 virus: Impact and treatment
por: Lahrich, S., et al.
Publicado: (2021)

Extraction and determination of flubendiamide insecticide in food samples: A review
por: Aghris, S., et al.
Publicado: (2022)

Current knowledge about the antivirals remdesivir (GS-5734) and GS-441524 as therapeutic options for coronaviruses
por: Amirian, E. Susan, et al.
Publicado: (2020)

Electrodeposition of silver onto carbon graphite and their catalysis properties toward thiamethoxam reduction: application in food and beverage samples
por: Ajermoun, N., et al.
Publicado: (2020)

Electrochemical impedance spectroscopy measurements for determination of derivatized aldehydes in several matrices
por: Boumya, W., et al.
Publicado: (2017)

Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease
por: Agostini, Maria L., et al.
Publicado: (2018)

Remdesivir (GS-5734) Impedes Enterovirus Replication Through Viral RNA Synthesis Inhibition
por: Ye, Wei, et al.
Publicado: (2020)

Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection
por: de Wit, Emmie, et al.
Publicado: (2020)

Corrigendum: Remdesivir (GS-5734) Impedes Enterovirus Replication Through Viral RNA Synthesis Inhibition
por: Ye, Wei, et al.
Publicado: (2020)

Phosphoramidate Prodrugs Continue to Deliver, The Journey of Remdesivir (GS-5734) from RSV to SARS-CoV-2
por: Mackman, Richard L.
Publicado: (2022)

Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys
por: Warren, Travis K., et al.
Publicado: (2016)

GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses
por: Lo, Michael K., et al.
Publicado: (2017)

Evidence for the Effectiveness of Remdesivir (GS-5734), a Nucleoside-Analog Antiviral Drug in the Inhibition of I (K(M)) or I (K(DR)) and in the Stimulation of I (MEP)
por: Chang, Wei-Ting, et al.
Publicado: (2020)

Electrochemical determination of paraquat in citric fruit based on electrodeposition of silver particles onto carbon paste electrode
por: Farahi, Abdelfettah, et al.
Publicado: (2015)

Review on the global epidemiological situation and the efficacy of chloroquine and hydroxychloroquine for the treatment of COVID-19
por: Saqrane, S., et al.
Publicado: (2020)

Broad-spectrum Investigational Agent GS-5734 for the Treatment of Ebola, MERS Coronavirus and Other Pathogenic Viral Infections with High Outbreak Potential
por: Jordan, Robert, et al.
Publicado: (2017)

Practical and Highly Efficient Synthesis of Remdesivir from GS-441524
por: Hu, Tianwen, et al.
Publicado: (2022)

Population Pharmacokinetics of Remdesivir and GS-441524 in Hospitalized COVID-19 Patients
por: Leegwater, E., et al.
Publicado: (2022)

An efficient synthesis of RNA containing GS-441524: the nucleoside precursor of remdesivir
por: Moorthy, Ramkumar, et al.
Publicado: (2021)

Transplacental transfer of Remdesivir and GS‐441524: An ex vivo perfusion study
por: Louchet, Margaux, et al.
Publicado: (2023)

Remdesivir as a possible therapeutic option for the COVID-19
por: Al-Tawfiq, Jaffar A., et al.
Publicado: (2020)

Advantages of the Parent Nucleoside GS-441524 over Remdesivir for Covid-19 Treatment
por: Yan, Victoria C., et al.
Publicado: (2020)

Biotransformation and transplacental transfer of the anti-viral remdesivir and predominant metabolite, GS-441524 in pregnant rats
por: Yang, Ling, et al.
Publicado: (2022)

Oral prodrug of remdesivir parent GS-441524 is efficacious against SARS-CoV-2 in ferrets
por: Cox, Robert M., et al.
Publicado: (2021)

Removal of Remdesivir’s Metabolite GS-441524 by Hemodialysis in a Double Lung Transplant Recipient with COVID-19
por: Lê, Minh Patrick, et al.
Publicado: (2020)

Interpatient variability in the pharmacokinetics of remdesivir and its main metabolite GS-441524 in treated COVID-19 subjects
por: Tempestilli, Massimo, et al.
Publicado: (2022)

Validation of LC-MS/MS methods for determination of remdesivir and its metabolites GS-441524 and GS-704277 in acidified human plasma and their application in COVID-19 related clinical studies
por: Xiao, Deqing, et al.
Publicado: (2021)

Structural Insights into Plasticity and Discovery of Remdesivir Metabolite GS-441524 Binding in SARS-CoV-2 Macrodomain
por: Ni, Xiaomin, et al.
Publicado: (2021)

Population pharmacokinetic modeling of GS‐441524, the active metabolite of remdesivir, in Japanese COVID‐19 patients with renal dysfunction
por: Sukeishi, Asami, et al.
Publicado: (2021)

Can remdesivir and its parent nucleoside GS-441524 be potential oral drugs? An in vitro and in vivo DMPK assessment
por: Xie, Jiashu, et al.
Publicado: (2021)

Outcomes of treatment of cats with feline infectious peritonitis using parenterally administered remdesivir, with or without transition to orally administered GS‐441524
por: Coggins, Sally J., et al.
Publicado: (2023)

Thirty‐two cats with effusive or non‐effusive feline infectious peritonitis treated with a combination of remdesivir and GS‐441524
por: Green, Jodie, et al.
Publicado: (2023)

Biased β-Agonists Favoring Gs over β-Arrestin for Individualized Treatment of Obstructive Lung Disease
por: Tokmakova, Alina, et al.
Publicado: (2022)

Remdesivir and GS-441524 Retain Antiviral Activity against Delta, Omicron, and Other Emergent SARS-CoV-2 Variants
por: Pitts, Jared, et al.
Publicado: (2022)

The Potential Protective Role of GS-441524, a Metabolite of the Prodrug Remdesivir, in Vaccine Breakthrough SARS-CoV-2 Infections
por: Zhu, JiaYi, et al.
Publicado: (2022)

Population pharmacokinetics and exposure–clinical outcome relationship of remdesivir major metabolite GS‐441524 in patients with moderate and severe COVID‐19
por: Tamura, Ryo, et al.
Publicado: (2023)

Eco-friendly spectrophotometric methods for determination of remdesivir and favipiravir; the recently approved antivirals for COVID-19 treatment
por: Elama, Heba Samir, et al.
Publicado: (2023)

Available Evidence and Ongoing Clinical Trials of Remdesivir: Could It Be a Promising Therapeutic Option for COVID-19?
por: Sisay, Mekonnen
Publicado: (2020)

Broad-spectrum in vitro antiviral activity of ODBG-P-RVn: an orally-available, lipid-modified monophosphate prodrug of remdesivir parent nucleoside (GS-441524)
por: Lo, Michael K., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_a4ujij1bg08tabnh1cav26bu8c